Adherence challenges with pre-exposure prophylaxis (PrEP) could be overcome if experimental long-acting HIV drug is found to be effective and acceptable.
Near-universal uptake of HIV testing among men who were given self-tests by their partners in Kenya shows its feasibility as an intervention to reach hard-to-reach groups.
Injecting drug use accounted for 9% of all new HIV infections in the USA in 2014 – but new demographic trends among people who inject drugs present new challenges for the HIV response.
The world’s second largest antiretroviral treatment programme is now reaching just under half of all those living with HIV in India, but challenges remain to achieve UNAIDS’ 90-90-90 Fast-Track targets.